Newer monoclonal antibodies for hematological malignancies

Since the approval of rituximab in 1997, monoclonal antibodies have come to play an important role in the therapy of hematological malignancies. Rituximab, gemtuzumab ozogamicin, and alemtuzumab are US Food and Drug Administration–approved for treatment of B-cell lymphomas, acute myeloid leukemia, a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Experimental hematology 2008-07, Vol.36 (7), p.755-768
Hauptverfasser:	Castillo, Jorge, Winer, Eric, Quesenberry, Peter
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced Basic Science Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Antibody Specificity - immunology Antigens, Neoplasm - immunology Antineoplastic Agents - immunology Antineoplastic Agents - therapeutic use Clinical Trials as Topic Hematologic Neoplasms - immunology Hematologic Neoplasms - therapy Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation Humans Leukemia, Lymphocytic, Chronic, B-Cell - immunology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Leukemia, Myeloid, Acute - immunology Leukemia, Myeloid, Acute - therapy Lymphoma, B-Cell - immunology Lymphoma, B-Cell - therapy Mice United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!